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Aims Circulating endogenous, dietary, and foreign chemicals can contribute to vascular dysfunction. The mechanism by
which the vasculature protects itself from these chemicals is unknown. This study investigates whether the pregnane
X receptor (PXR), the major transcriptional regulator of hepatic drug metabolism and transport that responds to
such xenobiotics, mediates vascular protection by co-ordinating a defence gene programme in the vasculature.
Methods
and results
PXR was detected in primary human and rat aortic endothelial and smooth muscle cells (SMC) and blood vessels
including the human and rat aorta. Metabolic PXR target genes cytochrome P450 3A, 2B, 2C, and glutathione S-trans-
ferase mRNA and activity were induced by PXR ligands in rodent and human vascular cells and absent in the aortas
from PXR-null mice stimulated in vivo or in rat aortic SMC expressing dominant-negative PXR. Activation of aortic
PXR by classical agonists had several protective effects: increased xenobiotic metabolism demonstrated by bioactiva-
tion of the pro-drug clopidogrel, which reduced adenosine diphosphate-induced platelet aggregation; increased ex-
pression of multidrug resistance protein 1, mediating chemical efflux from the vasculature; and protection from
reactive oxygen species-mediated cell death.
Conclusion PXR co-ordinately up-regulates drug metabolism, transport, and antioxidant genes to protect the vasculature from
endogenous and exogenous insults, thus representing a novel gatekeeper for vascular defence.
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1. Introduction
The vascular wall serves as a barrier controlling the movement of
solutes, fluids, and cells from the vascular space to the tissues and
as such is exposed to circulating chemicals from both endogenous
and foreign sources, including drugs and dietary and environmental
contaminants.1 These chemicals can contribute to vascular dysfunc-
tion and the development of cardiovascular disease.2 Yet, little consid-
eration has been given to how the vasculature regulates and protects
itself and therefore all organs from such insults.
The body defends itself from chemical insults by biotransforming
chemicals and eliminating the metabolites using a system of
enzymes and transport proteins in the liver and intestine. The
xenosensing pregnane X receptor (PXR; NR1I2) is central to this
process.3 PXR, a member of the nuclear receptor superfamily of
ligand-dependent transcription factors, can be activated by a
variety of structurally distinct ligands, including drugs (e.g. dihydro-
pyridine calcium channel blockers),3 environmental contaminants
(e.g. polychlorinated biphenyls),4 and endogenous compounds
such as bile acids, oxysterols, and steroid hormones3,5 and in
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response regulates the enterohepatic defence system at a transcrip-
tional level. Activated PXR binds to response elements in the pro-
moters and up-regulates the transcription of Phase I and II
drug-metabolizing enzymes, e.g. cytochrome P450 (CYP)s and
glutathione S-transferases (GSTs), and transporters, e.g. multidrug
resistance protein 1 (MDR1).3,6
Numerous CYPs are expressed in vascular cells, where they produce
endogenous mediators such as epoxyeicosatrienoic acids (EETs).7 This
includes CYPs potentially regulated by PXR; CYP3A, 2B, and 2C.8–10
However, neither the roles of any of these CYPs in drug metabolism
within the vasculature nor the contribution of PXR-regulated xenosen-
sing to the protective homeostatic barrier role of the vasculature has
been investigated. Vascular expression of PXR mRNA has been shown
previously in rat and Psammomys obesus gerbil thoracic aortic smooth
muscle cells (SMC), rat, pig, and human brain capillary endothelial
cells, and mouse mesenteric arteries.11–18 The latter was indicated in
regulating vasodilation during pregnancy via up-regulation of CYP epox-
ygenases.18 Here, we show that PXR is expressed in the vasculature
across species, where it co-ordinates a gene programme of Phase I
and II drug-metabolizing enzymes and transporters, providing a mechan-
ism by which the vasculature can protect itself and the underlying tissues
from circulating xenobiotic and endobiotic insults.
2. Methods
For detailed methods and reagent sources, see Supplementary material
online.
2.1 Immunohistochemistry
Immunohistochemistry was performed on Ambion Human LandMarkTM
LD cardiovascular tissue microarrays as described previously.19
Dewaxed sections were blocked with 10% goat preimmune serum, incu-
bated with 1:50 dilution of rabbit anti-PXR antibody (Santa Cruz Biotech-
nology, CA, USA) overnight and processed according to the avidin–biotin
complex method (Vector Labs, Peterborough, UK) using a 1:100 dilution
of Vector goat anti-rabbit IgG biotinylated secondary antibody. Control
sections were treated as above but incubated overnight in the absence
of primary antibody. The slides were counterstained with haematoxylin.
2.2 Cell culture
Rat aortic SMC (RASMC; WKY3m-22), Huh-7, and HepG2 cells were
grown and maintained in Dulbecco’s modified Eagle’s medium containing
10% foetal bovine serum (DMEM) as described previously.20 For
dominant-negative experiments, RASMC were transfected with a 2:5
complex of dominant-negative PXR (PXR-DN)21 or empty vector
pcDNA 3.1 V5 His plasmid DNA and LipofectamineTM 2000 (Invitrogen,
Paisley, UK) as previously described22 for 24 h prior to treatment. Primary
human aortic endothelial cells (HAEC) and human aortic SMC (HASMC)
were obtained from Promocell (Heidelberg, Germany) and cultured
according to Promocell recommendations. Due to species differences,
pregnenolone 16a-carbonitrile (PCN; 10 mmol/L) and rifampicin
(10 mmol/L) were used to activate rodent and human PXR, respectively.
2.3 Organ culture
Wistar rat aorta organ culture was performed essentially as described
previously.23 Animals were cared for in accordance with the Home
Office Guidance in the Operation of the Animals (Scientific Procedures)
Act 1986. Animals were administered buprenorphine analgesic (0.03 mg/
kg subcutaneously) prior to anaesthesia with sodium thiopentone (85 mg/
kg ip), approved in Home office project number PPL 70/7055, protocol
4. Anaesthesia was monitored by reaction to foot pinching at 15 min
intervals and respiration monitoring and maintained by supplementary
infusions of sodium thiopentone. The animal was euthanized prior to
aorta removal by removal of the heart under deep anaesthetic. Aortas
were cleaned and equilibrated for an hour in DMEM. Aortas were
treated with vehicle [dimethyl sulfoxide (DMSO)] or 10 mmol/L PCN
for 24 h with or without 100 mmol/L (+)-clopidogrel hydrochloride for
the final hour of PCN treatment. Ten microlitres of this conditioned
media was incubated with 100 mL of human platelet-rich plasma (PRP)
for 30 min at 378C for platelet aggregation studies. Human blood was col-
lected by venepuncture into tri-sodium citrate (3.2% w/v final) and centri-
fuged (175 g, 15 min) to obtain PRP. Aggregation of the PRP in response
to 0.1 mmol/L adenosine diphosphate (ADP) was measured by a modified
96-well plate light transmission method.24 The platelet study was
approved by the St Thomas’s Hospital Research Ethics Committee (Ref.
07/Q0702/24), conducted according to the Declaration of Helsinki and
all volunteers gave written informed consent prior to providing blood
samples. The aortas were used for reverse transcription–polymerase
chain reaction (RT–PCR) analysis.
2.4 RT–PCR analysis
RT–PCR was performed using standard techniques as described in Sup-
plementary material online. Copy DNA (cDNA) was synthesized from
2 mg total RNA and extracted from cultured cells or rat aorta using
TRIzol reagent (Invitrogen). PCR was performed using GoTaqw Flexi
DNA polymerase according to the manufacturer’s protocol (Promega).
PCR products were size fractionated and visualized with a 1.5% agarose
gel containing ethidium bromide. For quantification, bands were analysed
using ImageJ (NIH, Bethesda, MD, USA) and presented as a ratio to
b-actin.
2.5 Real-time PCR analysis
cDNA was prepared from 1 to 5 mg total RNA extracted from cultured
vascular cells, mouse aorta, positive control mouse, and rat liver and
Huh-7 (human hepatoma) cells with TRIzol reagent. Real-time PCR was
performed using the primers, probes, and reagents listed in Supplemen-
tary material online using glyceraldehyde-3-phosphate dehydrogenase as
an internal control. For PXR detection, absolute quantification was per-
formed using a genomic DNA (Promega) standard curve.
2.6 PXR knockout mice
Mouse care and procedures were approved by the Animal Ethics Com-
mittee, National Institute of Environmental Health Sciences, and con-
formed to the Guide for Care and Use of Laboratory Animals
published by the US National Institutes of Health. Genetically matched
wild-type (PXR+/+) and null (PXR–/–) mice in 129sv/C57BL6 mixed
background,25 which had been backcrossed with C57BL6 six times,
were randomly divided into two groups (n ¼ 3/group) and were treated
with PCN (20 mg/kg body weight ip) or vehicle (DMSO) for 24 h. The
mice were killed by CO2 inhalation as described in NIEHS Animal Re-
source SOP 8.602 and the aortas removed.
2.7 Non-lytic P450-GloTM assay for CYP3A4
CYP3A activity was measured using a substrate from Promega that lumi-
nesces after metabolism. RASMC were cultured in 96-well plates and
treated with PCN (10 mmol/L) for 48 h, changing the media daily. Cells
were incubated at 378C for 4 h with the CYP3A4 substrate luciferin-PFBE
(1:40 dilution) in the presence of 10 mmol/L ketoconazole or a range of
clopidogrel concentrations. Luminescence in the conditioned media was
measured after 20 min room temperature incubation with an equal
volume of luciferin detection reagent.
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2.8 Cell viability
Cell viability was measured by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphe-
nyltetrazolium bromide (MTT) assay.26 RASMC treated with PCN
(10 mmol/L) for 24 h, followed by 3 h hydrogen peroxide (1 mmol/L) treat-
ment, were incubated for 30 min at 378C in DMEM containing 0.2 mg/mL
MTT. The medium was removed and the formazan precipitate dissolved
in DMSO. Absorbance was measured at 550 nm. The effect of PXR-DN
on hydrogen peroxide-induced cell death in living cells was measured indir-
ectly using green fluorescent protein (GFP) as a transfection marker, as
described previously; a 9:1 mixture of PXR-DN and GFP, totalling 0.6 mg
plasmid per well, was used.27 Twenty-four hour post-transfection cells
were treated as above. Fluorescent microscopy images were captured
from three (×200) magnification fields for each sample, which were pre-
pared in triplicate, and the number of GFP cells was counted.
2.9 Efflux assay
MDR1-mediated efflux was measured by rhodamine 123 fluorescent dye
as described previously.28 HAEC were cultured in 96-well plates and
treated with either vehicle (0.1% DMSO) or 10 mmol/L rifampicin for
24 h. Cells were loaded with 1 mmol/L rhodamine 123 at 378C in the
presence of 100 mmol/L verapamil (MDR1 inhibitor) for 10 min. After
washing on ice, the cells were incubated for 6 min in 200 mL Hanks’ buf-
fered salt solution at room temperature to allow rhodamine 123 efflux.
Fluorescence in the conditioned Hanks’ buffered salt solution was mea-
sured at 485 nm excitation and 535 nm emission.
2.10 Cellular GST and glutathione peroxidase
assays
Cellular GST and glutathione peroxidase (GPx) activity were measured as
described previously.29 Protein extracts were prepared by sonication and
centrifugation from RASMC treated for 24 h with either vehicle (0.1%
DMSO) or 10 mmol/L PCN. The protein concentration of the superna-
tants was determined by BioRad protein assay (Hemel-Hempstead, UK).
GST activity was measured by the change in absorbance at 340 nm of
1-chloro-2,4-dinitrobenzene (CDNB), due to enzyme-dependent forma-
tion of CDNB–glutathione conjugate, at 30 s intervals for 5 min at
room temperature. GST activity was calculated using the extinction coef-
ficient 9.6 mmol/L cm and the results were expressed as nmol CDNB–
glutathione conjugate formed per minute per milligram cellular protein.
GPx activity was measured by the change in absorbance at 340 nm due
to enzyme-dependent NADPH consumption at 30 s intervals for 5 min
at 378C. This measurement was based on the consumption of NADPH
by glutathione reductase in the reaction mix during the reduction in
GPx-generated glutathione disulfide. GPx activity was calculated using ex-
tinction coefficient 6.22 mmol/L cm and the results were expressed as
nmol NADPH consumed per minute per milligram cellular protein.
3. Results
3.1 PXR is expressed in human vasculature
PXR, the master regulator of enterohepatic drug metabolism and
transport,3 was detected in vascular SMC of the human aorta
(Figure 1A1a), in the cardiac muscle (Figure 1A2a), and in small
vessels in the heart (Figure 1A2c). PXR was expressed in positive
control tissues, liver (Figure 1A3a) and small intestine (Figure 1A4a)
and was absent in negative control tissue, spleen (Figure 1A5a). No
positive staining was observed when the primary antibody was
omitted (Figure 1A1–5b, controls).
3.2 PXR is expressed in vascular cells
in vitro
PXR mRNA was detected by real-time PCR in the PXR-positive con-
trols human hepatoma cell line Huh-7 and rat and mouse liver
(Figure 1B). PXR mRNA was also present in RASMC, HASMC,
Figure 1 PXR is expressed in cardiovascular tissue. (A) Immunor-
eactive PXR protein (brown immunoperoxidase) in the aorta (1a),
heart (2a) including vessels in the highlighted area of the heart
(2c), liver (3a), and small intestine (4a) but not the spleen (5a) or
when primary antibody was omitted (1–5b). Magnification ×200.
Scale bar represents 100 mm. (B) PXR mRNA in the rat liver
(n ¼ 2), RASMC (n ¼ 20), Huh-7 (n ¼ 3), HAEC (n ¼ 13),
HASMC (n ¼ 2), mouse aorta (n ¼ 4), and mouse liver (n ¼ 3).
Data represent the number of copies of PXR mRNA/ng total
RNA +SE.
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HAEC, and in the freshly harvested mouse and rat aorta (Figure 1B;
see Supplementary material online, Figure S1). PXR protein expression
was confirmed in HAEC, HASMC, and RASMC by western blotting
(see Supplementary material online, Figure S1).
3.3 PXR regulates Phase I drug metabolism
in vascular cells
PXR is considered a xenosensing receptor that co-ordinately regu-
lates the transcription of genes involved in drug metabolism and trans-
port in the liver and intestine.3 We hypothesized that PXR regulated a
similar defence gene programme in the vasculature, as summarized in
Figure 2.
PXR is known to regulate Phase I enzyme subfamilies CYP3A,
CYP2B, and CYP3A in the human and rodent liver.3 Similarly,
CYP3A23, CYP2B2, and CYP2C6 were significantly induced in
RASMC and in ex vivo cultured rat aorta in response to 10 mmol/L
PCN (Figure 3A). The equivalent human CYP isoforms CYP3A4,
CYP2B6, and CYP2C8 were induced by 10 mmol/L rifampicin in
HAEC and HASMC (see Supplementary material online, Table S2).
Consistent with known variations in human expression and human
hepatocyte primary cell culture for CYPs, there was a great variation
in basal expression of CYPs in human primary vascular cells; however,
there was a consistent induction of at least one CYP by PXR in the
majority of cultures.30,31 CYP3A23 mRNA induction was matched
by a similar induction of CYP3A activity after PCN treatment of
RASMC, which was inhibited by CYP3A inhibitor ketoconazole
(Figure 3B). However, when RASMC were transiently transfected
with either PXR-DN or control empty vector (pcDNA3.1),
Figure 2 PXR protects the vasculature against chemical and oxi-
dative insults. Activation of PXR in endothelial cells and SMC
induces transcription of Phase I and II drug-metabolizing enzymes
and transporters, e.g. CYP3A and GSTs, consequently altering meta-
bolic handling and enhancing endogenous homeostatic mediator
production, e.g. EETs in the vasculature. Oxidative stress response
genes, e.g. GPx, are also up-regulated, which with GSTs can
protect against oxidative damage.
Figure 3 PXR-dependent cytochrome P450 induction. Data rep-
resent fold change from vehicle (DMSO)-treated samples +SE
due to 24 h treatment with PCN (10 mmol/L in vitro; 20 mg/kg
body weight ip in vivo). (A) Densitometric analysis of semi-
quantitative RT–PCR for CYP3A23 (n ¼ 3), CYP2B2 (nRASMC¼ 6,
nAorta¼ 7), and CYP2C6 (n ¼ 3) in RASMC or ex vivo cultured
Wistar rat aorta normalized to b-actin control. (B) CYP3A activity
in RASMC was assessed as the conversion of CYP3A luminogenic
substrate over 4 h post-PCN treatment, with or without CYP3A in-
hibitor ketoconazole (10 mmol/L). n ¼ 4 triplicate samples. (C) Real-
time PCR for CYP3A23 (n ¼ 3) in RASMC transfected with either
control vector or PXR-DN plasmid normalized to GAPDH
control. (D) Real-time RT–PCR for Cyp2b10 (n ¼ 3) on in vivo
treated wild-type and PXR-null mice aorta, normalized to GAPDH
control. *P, 0.05 vs. vehicle (A, B, one-sample t-test; D, Mann–
Whitney non-parametric test). **P, 0.01 two-way ANOVA with
Bonferroni’s multiple comparison test.
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CYP3A23 mRNAwas significantly induced after PCN treatment in the
control RASMC but not in those transfected with PXR-DN
(Figure 3C). To further confirm PXR-dependent regulation of CYPs
in the vasculature, in vivo CYP induction in the PXR wild-type and
knockout mouse aorta was examined 24 h after ip PCN administra-
tion. Cyp2b10, the mouse equivalent of human CYP2B6, mRNA
was significantly induced in the aorta from wild-type mice but not
PXR-null mice after treatment with PCN (Figure 3D).
3.4 PXR activators induce functional
clopidogrel pro-drug conversion to the
active P2Y12 antagonist in the rat aorta
Clopidogrel is a commonly used anti-platelet drug, which inhibits ADP
responses by blocking the P2Y12 ADP receptor in platelets. Clopido-
grel is also a pro-drug that requires bioactivation by CYP1A2 and PXR
target genes CYP3A, CYP2B6, CYP2C9, and CYP2C19 to produce its
active P2Y12 ADP receptor inhibitor.
3,32,33 The CYP3A induced by
PCN in RASMC was able to accept clopidogrel as a substrate, as clo-
pidogrel competed with the luciferin-PFBE substrate in the CYP3A
assay (Figure 4A).
CYP3A, 2B, and 2C mRNA was significantly induced in ex vivo cul-
tured rat aorta in response to PCN (Figure 3A). Conditioned media
from rat aorta pre-incubated with PCN for 24 h and then treated
with clopidogrel (100 mmol/L) for 1 h was tested to see whether a
functional conversion of clopidogrel pro-drug had occurred. Human
PRP was stimulated with 1 mmol/L ADP (Figure 4B) to induce sub-
maximal aggregation (50% maximum aggregation). When condi-
tioned media was added to the PRP, ADP-induced aggregation was
significantly reduced (Figure 4B). In contrast, conditioned media
from the rat aorta incubated with either clopidogrel or PCN alone
did not alter ADP-induced aggregation.
3.5 PXR ligands regulate transport in
vascular cells
MDR1 [ATP-binding cassette subfamily B (ABCB1)], a PXR-regulated
efflux transporter actively translocates substrates across biological
membranes.6 Expression of MDR1 mRNA and efflux of Rhodamine
123, an MDR1-specific fluorescent substrate, was induced after PXR
ligand treatment of HAEC (Figure 5).
3.6 PXR ligands decrease oxidative stress in
vascular cells
PXR transcriptionally regulates the GST family of Phase II drug-
metabolizing enzymes, which protect against toxicity and oxidative
stress by conjugating glutathione to their substrates and by their
GPx activity.34,35 GSTM1 mRNA expression and GST and GPx activ-
ities (Figure 6A) were significantly induced after PCN treatment of
RASMC. To confirm whether this protected vascular cells against oxi-
dative damage, RASMC death was induced in a concentration-
dependent manner by H2O2 (data not shown). Pre-treatment of the
cells for 24 h with PCN reduced the H2O2-induced cell death at
similar levels as the GPx mimetic ebselen, whereas the non-
peroxidase antioxidant apocynin did not prevent the cell death
(Figure 6B and C; see Supplementary material online, Figure S2). Trans-
fection of RASMC with PXR-DN blocked the ability of PCN to
reduce H2O2-induced cell death (Figure 6D).
Figure 4 (A) Clopidogrel competes with CYP3A luminogenic sub-
strate for metabolism in RASMC. Data represent fold change (n ¼ 3
triplicate samples) from vehicle +SE. (B) PXR activation in the rat
aorta by PCN (10 mmol/L 24 h) enhances the anti-platelet aggrega-
tion effects of clopidogrel. Ten microlitres of conditioned media,
from ex vivo cultured rat aorta incubated with clopidogrel
(100 mmol/L 1 h post-PCN), were incubated with PRP for 30 min
prior to 1 mmol/L ADP stimulation. Data represent aggregation/mg
aortic protein as a percentage of control +SE, n ¼ 4, duplicate
samples; *P, 0.05 vs. vehicle control determined by one-sample
t-test.
Figure 5 PXR activation induces multidrug resistance protein 1
expression and activity. HAEC were treated with rifampicin
(10 mmol/L; 24 h) (A) Real-time PCR of MDR1 (n ¼ 6) normalized
to GAPDH control, expressed as the fold change from vehicle
(0.1% DMSO)-treated cells +SE. (B) MDR1-mediated efflux of
fluorescent substrate rhodamine 123, represented as a percentage
of vehicle control efflux +SE, n ¼ 8. *P, 0.05 vs. vehicle deter-
mined by paired Student’s t-test.
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4. Discussion
Exposure to chemicals from endogenous, dietary, and environmental
sources has been shown to contribute to the development of cardio-
vascular diseases.2 There is an established enterohepatic system re-
sponsible for protecting the body from these toxic insults, by
metabolizing the majority of these chemicals. Expression of PXR, a
master regulator of enterohepatic drug metabolism and transport,3
was detected in the human aorta and heart tissue sections, HAEC,
HASMC, RASMC, and rat and mouse aorta. This expression of PXR
in vascular cells contrast with a previous finding of no PXR in the
aorta and heart from C57/BL6 and 129 × 1/SvJ mice.36 However,
our data in combination with the detection of PXR mRNA in SMC
from obese Zucker rat and P. obesus gerbil thoracic aorta and in wild-
type mouse mesenteric arteries indicate that arterial PXR expression
is common across species and that the mRNA is translated into a
functional protein.11,12,18
The vascular endothelium expresses known hepatic drug-
metabolizing enzymes, such as CYPs, which produce endogenous
mediators by metabolism of compounds, such as arachidonic acid.7,9
To confirm PXR-regulated vascular Phase I metabolism, CYP induc-
tion was examined in primary RASMC. CYP3A23, CYP2B2, and
CYP2C6 were significantly induced in RASMC by PXR activation. In
addition, the up-regulation of CYP3A23 mRNA corresponded to an
induction of similar magnitude of CYP3A functional activity. Focused
cDNA microarrays showed that Phase I and II drug-metabolizing
enzymes and transporters were also expressed in and up-regulated
in a concerted manner by PXR activation in human vascular cells
(see Supplementary material online, Table S3), similar to the patterns
observed previously in human hepatocytes, rat liver, and wild-type but
not PXR knockout mouse liver.37,38 The induction of cytochrome
P450s from the 3A, 2B, and 2C subfamilies by PXR activation in
HAEC and HASMC was confirmed by RT–PCR. There was,
however, variability in basal CYP expression in the primary human
vascular cells, similar to observations in primary hepatocyte cultures,
where CYP expression and function decline with culture time and are
altered by disease.31
To establish whether PXR regulation of vascular drug-metabolizing
enzymes has a functional impact on the metabolism and therefore
efficacy of cardiovascular drugs directly in the vessel wall, the
anti-platelet aggregation drug clopidogrel was selected for testing.
Clopidogrel is a pro-drug that requires metabolism by CYP1A2 and
PXR target genes CYP3A, CYP2B6, CYP2C9, and CYP2C19 to
form an active metabolite that inhibits ADP-induced platelet activation
by irreversibly binding to the P2Y12 ADP platelet receptor.
3,32,33
Enhanced CYP transcription, e.g. allelic variant CYP2C19*17,
increases the bioactivation and patient responsiveness to clopido-
grel.39 Clopidogrel metabolic conversion is considered to occur ex-
clusively in the liver. Yet, in a cultured rat aorta system, PXR
activation up-regulated the transcription of clopidogrel-metabolizing
CYPs and induced clopidogrel bioactivation, generating an active
P2Y12 antagonist that inhibited platelet aggregation. This corresponds
to the clinical observations that PXR activation enhanced responsive-
ness to clopidogrel, whereas low polymorphic PXR expression corre-
lates with clopidogrel non-responsiveness,33 suggesting that PXR
represents a target to overcome resistance to clopidogrel treatment.
This is important as 25% of the patients with acute myocardial infarc-
tion undergoing coronary artery stenting are hyporesponsive or
Figure 6 PXR activation induces GST activity (n ¼ 5), GPx activity
(n ¼ 6), and GSTM1 mRNA expression (n ¼ 6) in RASMC treated
with PCN (10 mmol/L 24 h) (A). Data represent fold change in
enzyme activity or GSTM1:GAPDH ratio for real-time PCR from
vehicle (0.1% DMSO)-treated cells +SE. (B and C ) PXR activation
(10 mmol/L PCN, 24 h) protects RASMC from hydrogen peroxide
(1 mmol/L, 3 h post-PCN)-induced cell death. (B) Representative
photomicrographs of RASMC morphology post-treatment. Magnifi-
cation ×100. Scale bar represents 200 mm. (C) Data represent via-
bility as a percentage of control +SE (n ¼ 5 triplicate samples). (D)
Expression of PXR-DN prevents PXR activator-mediated protection
of RASMC viability. RASMC transfected with control vector
(pcDNA 3.1) or PXR-DN plasmid in the presence of GFP expres-
sion vector (pEGFPN-1) at a ratio of 9:1 were treated 24 h post-
transfection with 10 mmol/L PCN for 24 h and then 1 mmol/L
hydrogen peroxide for 3 h before GFP cells were counted by fluor-
escent microscopy. Data represent the mean from three (×200)
magnification fields per triplicate, from n ¼ 3 experiments +SE.
(A) *P, 0.05 vs. vehicle determined by one-sample t-test. (C )
*P, 0.05, (A) **P, 0.01 vs. control/vehicle determined by paired
Student’s t-test. (D) *P, 0.05, ***P, 0.001 determined by
two-way ANOVA with Bonferroni’s post hoc test.
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resistant to clopidogrel.40 Our results indicate for the first time the
drug metabolism capability of vascular cells, the systemic relevance
of which should be considered. Indeed, PCN-induced CYP3A in
RASMC accepted clopidogrel and simvastatin (see Supplementary
material online, Figure S3A) as substrates, in competition with the
CYP3 Aactivity assay substrate luciferin-PFBE. Simvastatin is a
widely used 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reduc-
tase inhibitor, metabolized by CYP3A.41 In addition to its
cholesterol-reducing effects, HMG-CoA reductase inhibition, and
thus high levels of simvastatin, directly induces vascular SMC apop-
tosis, via reduced RhoA prenylation activating a TGFb-Smad apop-
totic pathway.42,43 When RASMC were pre-treated with PCN, the
cells were protected from simvastatin cytotoxicity (see Supplemen-
tary material online, Figure S3B). Given the PXR dependence of the
protection (see Supplementary material online, Figure S3C ), increased
metabolism and clearance of simvastatin by PXR-up-regulated vascu-
lar CYP3A may play an important role in determining local simvasta-
tin efficacy. Overall, the induction of these key drug-metabolizing
enzymes in vascular cells, especially CYP3A4, which is responsible
for the oxidative metabolism of over 50% of pharmaceutical drugs
consumed by man, shows that the vasculature, a system of greater
mass than the liver,44 represents an important site for drug
metabolism.
The CYPs are not just involved in xenobiotic metabolism, and
CYP2C enzymes are the major endothelial epoxygenases, producing
EETs (important vascular homeostasis and anti-inflammatory signalling
molecules) from arachidonic acid.9 CYP3A and CYP2B can also con-
tribute to EET production.10,45 Hagedorn et al.18 indicated that hor-
monal activation of PXR during pregnancy initiates mesenteric
artery vasorelaxation by inducing CYP epoxygenases. Although PXR
mRNA was detected in mouse mesenteric arteries and vasorelaxation
could be inhibited by a CYP epoxygenase inhibitor, no direct induc-
tion of CYPs in the artery was shown.18 The local up-regulation of
CYPs in the vasculature we observed provides this missing link and
suggests that generally PXR may protect the vasculature from disrup-
tions to vascular homeostasis and inflammation and regulate tone.
This is in contrast to a recent report, which attributed CYP2C induc-
tion by PXR ligands to the other xenosensing receptor, constitutive
androstane receptor (CAR), as human saphenous vein endothelial
cells and umbilical vein endothelial cell line ECV304 did not express
PXR.3,46 This may highlight a difference between venous- and arterial-
derived endothelial cells, because in addition to HAEC, we have
detected PXR expression in human coronary artery endothelial
cells but could not detect PXR in human umbilical vein endothelial
cells (unpublished data). CAR is detected in both human HAEC and
HASMC on the cDNA arrays and in RASMC by RT–PCR (unpub-
lished data).
As endothelial cells form a barrier between the circulation and the
underlying tissues, we examined whether MDR1 actively transported
drugs across the endothelial barrier and was regulated by PXR as in
the liver.6 MDR1 mRNA and activity was induced after PXR ligand ri-
fampicin treatment, indicating that vascular PXR-mediated transport is
not limited to blood–brain barrier endothelial cells as previously
thought,13,17 but that similar to the liver, PXR in vascular cells can
co-ordinately regulate transport as well as drug metabolism, which
may impact on the bioavailability of cardiovascular drugs.47 In addition,
MDR1 transports free cholesterol into and out of cells and therefore
changes in MDR1 could potentially be harnessed to reduce choles-
terol accumulation in atherosclerotic lesions.48
Data from the cDNA arrays indicated that many Phase II conjugat-
ing drug-metabolizing enzymes from the GST and SULT families were
up-regulated by PXR (see Supplementary material online, Table S3).
These enzymes play an important role in protection from toxic and
oxidative stress. GSTs can protect against oxidative damage by conju-
gating glutathione to their substrates (xenobiotics or products of oxi-
dative stress) and by selenium-independent GPx activity.34,35 In
endothelial cells, GSTA4 protects against hydrogen peroxide-induced
apoptosis in vitro,35 similar to the PXR-dependent protection we
observed here in RASMC after PXR-mediated induction of GST activ-
ity. The cDNA arrays showed GSTM1 up-regulation in HAEC and
HASMC by PXR, which was confirmed by real-time PCR in
RASMC. Recent work by Yang et al.49 has linked reduced GSTM1 ex-
pression to decreased clearance of superoxide and thus increased
oxidative stress in RASMC from atherosclerosis susceptible C57BL/
6 mice. In addition, PXR activation-induced GPx activity, which
given the protection against hydrogen peroxide-induced cell death
by PCN was the same as a GPx mimetic, indicates a contribution of
induced peroxidase activity to the protective effect. Here, for the
first time in any tissue, PXR is shown to protect against oxidative
stress, co-ordinating an antioxidant response in vascular cells, inducing
total GST and GPx activity, and protecting against oxidative
stress-induced cytotoxicity.
In summary, PXR is expressed in the vasculature, where it
co-ordinately regulates the expression and activity of Phase I and II
drug-metabolizing enzymes, transporters, and oxidative stress re-
sponse genes (Figure 2). Consequently, PXR activation alters the effi-
cacy of well-known cardiovascular drugs clopidogrel and simvastatin
in vascular cells. This demonstrates the importance of considering
the vasculature and PXR in the metabolic handling and tissue distribu-
tion of cardiovascular drugs, nutritional components, and xenobiotics,
with implications in the understanding of adverse reactions, drug–
drug interactions, and individual patient responses. Importantly, this
study has not only confirmed that PXR regulates the same chemical
defence system in the vasculature as in the liver, but expanded that
defence system to include protection against oxidative stress,
making PXR a novel gatekeeper for vascular defence.
Supplementary material
Supplementary material is available at Cardiovascular Research online.
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